Skip to content

Simulated Amniotic Fluid Solution in Neonates Recovering From GIT Surgeries

Simulated Amniotic Fluid Like Solution Enterally Administrated in Neonates Recovering From GIT Surgeries

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03302338
Enrollment
40
Registered
2017-10-05
Start date
2015-07-31
Completion date
2018-10-31
Last updated
2017-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Necrotizing Enterocolitis

Keywords

Feeding intolerance, Simulated amniotic fluid like solution, Necrotizing enterocolitis

Brief summary

Amniotic fluid plays a significant role in fetal gut maturation and development. The human fetus swallows over 200 ml of amniotic fluid per kilogram of weight each day and such swallowing is essential for normal small bowel development.Growth factors found in the amniotic fluid have been shown to promote proliferation of fetal intestinal cells. As feeding intolerance is a common problem among neonates recovering from surgery for congenital bowel abnormalities, the investigators will study the role of enteral administration of simulated amniotic fluid solution in prevention of feeding intolerance and NEC in neonates recovering from GIT surgeries.

Detailed description

Neonates with congenital GIT anomalies will participate after being operated. Participants will be followed for the duration of hospital stay until discharge or death.

Interventions

DRUGSAFE group

simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.

DRUGplacebo group

distilled water 20 ml/kg/day for maximum of 7 days.

Sponsors

Rania Ali El-Farrash
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 28 Days
Healthy volunteers
No

Inclusion criteria

* Neonates with operable congenital bowel abnormalities

Exclusion criteria

* Critically ill babies. * Presence of any contraindications to enteral feeding

Design outcomes

Primary

MeasureTime frameDescription
Signs of feeding intolerancethrough study completion, an average of 1 yearFeeding intolerance defined as distended loops of bowel, bilious vomiting, large pre-feeding gastric residuals more than 20% of each feed, diarrhea, occult or gross blood in stools, abdominal wall erythema or ecchymosis

Secondary

MeasureTime frameDescription
Necrotizing enterocolitisThe outcome measure will be assessed within 2 months• Clinical signs of suspected NEC (abdominal distension, increased volume of gastric aspirate, bile stained aspirate, and / or apnea or bradycardia), and Bell's modified criteria for staging (Bell et al., 1978).
hospital staythrough study completion, an average of 1 yearduration on hospitalization
mortalityhe outcome measure will be assessed within 2 monthsdeath

Countries

Egypt

Contacts

Primary ContactRania A El-Farrash, MD
raniafarrash@hotmail.com00201222208550

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026